V., Labhsetwar, S., & LeQuang, J
FDA-Approved Semaglutide: BMI to Qualify for Wegovy Treatment To qualify for Wegovy (semaglutide) , adults must have a Body Mass Index (BMI) of 30 or higher, or a BMI between 27 and 29.9 with at least one weight-related health condition
it is the reason the honest answer to the title is partly, and probably less over time rather than a flat yes. Safety, Gastrointestinal Tolerability, and the Postprandial Trade-off The same gastric and central mechanisms that could deliver postprandial benefit are also the source of cagrilintides most common adverse effects, and this trade-off is worth stating without spin
10.3390/antiox12071425 100 SchaffertC.-S.DuryeeM
They are the same compound